bacampicillin and Sinusitis

The clinical effect and the penetration of ampicillin into sinus secretion after oral administration of bacampicillin was studied in 47 patients with acute maxillary sinusitis allocated at random in treatment with 400 mg bacampicillin 3 times or 1200 mg twice daily. The overall clinical effect was similar and was assessed as "good" in 23/25 patients treated with 400 mg doses and in 19/22 treated with 1200 mg. Adverse reactions were reported by 4 patients. The concentrations of ampicillin obtained in sinus secretion were proportional to the dose given. The highest values after 400 mg bacampicillin were approximately 0.6 mg/l and after 1200 mg about 2 mg/l. Both dosages are applicable to treatment of acute maxillary sinusitis.

Topics: Acute Disease; Adult; Age Factors; Ampicillin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Maxillary Sinus; Middle Aged; Radiography; Sex Factors; Sinusitis

Topics: Ampicillin; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Humans; Maxillary Sinus; Radiography; Sinusitis; Time Factors

Topics: Acute Disease; Adolescent; Adult; Aged; Ampicillin; Chronic Disease; Female; Humans; Laryngitis; Lymphadenitis; Male; Middle Aged; Otitis Externa; Pharyngitis; Sinusitis; Tonsillitis

Topics: Acute Disease; Adolescent; Adult; Aged; Ampicillin; Female; Humans; Male; Maxillary Sinus; Middle Aged; Sinusitis

Topics: Acute Disease; Adult; Aged; Ampicillin; Bronchitis; Female; Humans; Male; Middle Aged; Sinusitis

Forty outpatients with sinusitis were treated with equimolar doses of Ampicillin (556 mg) of Bacampicillin (800 mg) three times daily in a doubleblind fashion. To control the efficiency of the therapy the number of leukocytes, sedimentation rate, subjective and objective symptomes were evaluated before the first dose and on the 2nd and 10th day. On the 1st day nasal secretions were collected at the time the first dose was given and 1, 2, and 3 h later. In these samples the concentrations of the antibiotic, of protein and albumin were determined. The amount of nasal secretions collected as well as the protein and albumin content remains fairly constant during the experiment. The concentration of Bacampicillin in nasal secretions reaches its maximum of 0.92 microgram/ml 1 h after the application whereas with Ampicillin it is 0.59 microgram/ml after 2 h. These values correspond to the concentrations which were found in normal test persons. The clinical result of the therapy is slightly better with Bacampicillin only if patients with severe sinusitis were taken into account. In the patients with moderate or slight symptoms no difference was found. Two of the patients which were treated with Ampicillin had to stop the therapy because of severe diarrhoe. When using Bacampicillin no patients had diarrhoe. This study shows that Bacampicillin (as an inactive ester of Ampicillin) is resorbed quicker and gives higher concentrations in the nasal secretions. Thus, the therapeutic effect is better in severe cases as compared to Ampicillin. Moreover, the side effects are less.

Topics: Albumins; Ampicillin; Anti-Bacterial Agents; Humans; Mucus; Nasal Mucosa; Proteins; Sinusitis